MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

35.66 2

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

34.39

Максимум

35.68

Ключови измерители

By Trading Economics

Приходи

33M

-48M

Продажби

-2.6M

106M

Марж на печалбата

-45.487

Служители

1,869

EBITDA

19M

-56M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+66.11% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

563M

3.9B

Предишно отваряне

33.66

Предишно затваряне

35.66

Настроения в новините

By Acuity

50%

50%

157 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.07.2025 г., 15:46 ч. UTC

Значими двигатели на пазара

BitMine Shares Fall After Closing of $250 Million Private Placement

9.07.2025 г., 23:44 ч. UTC

Пазарно говорене

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

9.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9.07.2025 г., 22:59 ч. UTC

Пазарно говорене

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9.07.2025 г., 22:59 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

9.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

9.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.07.2025 г., 20:26 ч. UTC

Печалби

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9.07.2025 г., 19:18 ч. UTC

Пазарно говорене

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9.07.2025 г., 19:03 ч. UTC

Пазарно говорене

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9.07.2025 г., 18:31 ч. UTC

Пазарно говорене

Some Fed Officials Supported Considering July Cut -- Market Talk

9.07.2025 г., 17:07 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk -2-

9.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

9.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.07.2025 г., 16:14 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

9.07.2025 г., 16:14 ч. UTC

Пазарно говорене

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9.07.2025 г., 16:14 ч. UTC

Придобивния, сливания и поглъщания

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9.07.2025 г., 16:12 ч. UTC

Пазарно говорене

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9.07.2025 г., 16:08 ч. UTC

Пазарно говорене

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9.07.2025 г., 15:31 ч. UTC

Значими двигатели на пазара

BitMine Shares Fall After Closing of $250M Private Placement

9.07.2025 г., 15:31 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9.07.2025 г., 15:27 ч. UTC

Пазарно говорене

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9.07.2025 г., 14:36 ч. UTC

Придобивния, сливания и поглъщания

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9.07.2025 г., 14:31 ч. UTC

Придобивния, сливания и поглъщания

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9.07.2025 г., 14:26 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

9.07.2025 г., 14:26 ч. UTC

Пазарно говорене

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

66.11% нагоре

12-месечна прогноза

Среден 58.04 USD  66.11%

Висок 75 USD

Нисък 38.2 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

5

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

157 / 376 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.